文献速递介入腹部DSACTMR

药物洗脱微球经动脉化疗栓塞联合免疫检查点抑制剂治疗肝细胞癌的安全性评估:治疗间隔小于一个月时肝脓肿风险增加

Safety evaluation of combination treatment of drug-eluting bead transarterial chemoembolization and immune checkpoint inhibitors for hepatocellular carcinoma: An increased risk of liver abscess with treatment interval less than one month.
PubMed 文献 · Eur J Radiol · 2023-12-15

该回顾性单机构研究纳入208例接受DEB-TACE的肝细胞癌患者,其中50例在DEB-TACE前后一个月内接受ICIs治疗(DEB-ICI组),158例仅接受DEB-TACE(DEB组)。DEB-ICI组肝脓肿发生率显著高于DEB组(14.0% vs 5.1%,P=0.0337),联合ICIs是DEB-TACE后肝脓肿的独立危险因素(OR=3.0523,95%CI 1.0474-8.8947,P=0.0409)。作者结论认为间隔小于一个月的联合治疗增加肝脓肿风险,对此类患者需更加谨慎。

要点

  • DEB-ICI组肝脓肿发生率14.0%,显著高于DEB组的5.1%(P=0.0337)。
  • 联合ICIs是DEB-TACE后肝脓肿的独立危险因素(OR=3.0523,95%CI 1.0474-8.8947)。
  • DEB-ICI组中先接受ICIs再行DEB-TACE者肝脓肿发生率23.8%,高于先行DEB-TACE者的6.9%(P=0.0922)。

核心结论

  • 间隔小于一个月的DEB-TACE联合ICIs治疗增加DEB-TACE后肝脓肿风险,对接受短间隔ICIs和DEB-TACE的HCC患者需更加谨慎。

研究设计与样本

  • 回顾性单机构研究,共纳入208例接受DEB-TACE的HCC患者,其中50例在距DEB-TACE小于一个月内接受ICIs归入DEB-ICI组,其余158例归入DEB组;记录DEB-TACE前及术后三个月的ALBI评分评估肝功能变化,比较两组DEB-TACE后三个月内的不良事件。

诊断标准与关键数值

  • DEB-ICI组肝脓肿发生率14.0% vs DEB组5.1%(P=0.0337);单因素logistic回归显示联合ICIs为DEB-TACE后肝脓肿的独立危险因素(OR=3.0523,95%CI 1.0474-8.8947,P=0.0409);主观血管造影化疗栓塞终点量表及联合靶向治疗在本研究人群中为无显著意义的危险因素;DEB-ICI组中先接受ICIs者肝脓肿发生率23.8% vs 先接受DEB-TACE者6.9%(P=0.0922)。

临床应用与阅片要点

  • 作者结论认为,间隔小于一个月的DEB-TACE联合ICIs治疗增加肝脓肿风险,对接受短间隔ICIs和DEB-TACE的HCC患者需更加谨慎。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To analyze the safety of combination treatment comprising drug-eluting bead transarterial chemoembolization (DEB-TACE) and immune checkpoint inhibitors (ICIs) in hepatocellular carcinoma (HCC).

METHOD: In total, 208 HCC patients receiving DEB-TACE were enrolled for this retrospective single-institution study. Among them, 50 patients who received ICIs at an interval less than one month from DEB-TACE were categorized into the DEB-ICI group; the remaining 158 patients were categorized into the DEB group. Albumin-bilirubin (ALBI) score before and at three months after DEB-TACE were recorded to evaluate liver function changes. Adverse events within three months after DEB-TACE were considered TACE-related and were compared between the two groups.

RESULTS: The DEB-ICI group had significantly higher incidence of liver abscess than the DEB group (14.0 % versus 5.1 %, p-value = 0.0337). No significant difference in the other TACE-related adverse events and change of ALBI score between the groups. Univariate logistic regression confirmed that combination with ICIs was an independent risk factor for liver abscess after DEB-TACE (odds ratio = 3.0523, 95 % confidence interval: 1.0474-8.8947, p-value = 0.0409); other parameters including subjective angiographic chemoembolization endpoint scale and combined targeted therapy were nonsignificant risk factors in this study population. In the DEB-ICI group, patients who received ICIs before DEB-TACE exhibited a trend toward liver abscess formation compared with those who received DEB-TACE before ICIs (23.8 % versus 6.9 %, p-value = 0.0922).

CONCLUSIONS: Combination treatment involving DEB-TACE and ICIs at an interval less than one month increased the risk of liver abscess after DEB-TACE. Greater caution is therefore warranted for HCC patients who receive ICIs and DEB-TACE with this short interval.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Chiu SH, Lin HH, Feng AC, et al. Safety evaluation of combination treatment of drug-eluting bead transarterial chemoembolization and immune checkpoint inhibitors for hepatocellular carcinoma: An increased risk of liver abscess with treatment interval less than one month. Eur J Radiol. 2023. PMID: 38185027. doi:10.1016/j.ejrad.2023.111266

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。